Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/8572
Full metadata record
DC FieldValueLanguage
dc.rights.licenseBY-NC-ND-
dc.contributor.authorGazdic, Marina-
dc.contributor.authorVolarevic, Vladislav-
dc.contributor.authorRandall Harrell C.-
dc.contributor.authorFellabaum, Crissy-
dc.contributor.authorJovicic, Nemanja-
dc.contributor.authorArsenijevic, Nebojsa-
dc.contributor.authorStojkovíc M.-
dc.date.accessioned2020-09-19T16:07:26Z-
dc.date.available2020-09-19T16:07:26Z-
dc.date.issued2018-
dc.identifier.issn1661-6596-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/8572-
dc.description.abstract© 2018 by the authors. Licensee MDPI, Basel, Switzerland. Spinal cord injury (SCI), a serious public health issue, most likely occurs in previously healthy young adults. Current therapeutic strategies for SCI includes surgical decompression and pharmacotherapy, however, there is still no gold standard for the treatment of this devastating condition. Inefficiency and adverse effects of standard therapy indicate that novel therapeutic strategies are required. Because of their neuroregenerative and neuroprotective properties, stem cells are a promising tool for the treatment of SCI. Herein, we summarize and discuss the promising therapeutic potential of human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and ependymal stem/progenitor cells (epSPC) for SCI.-
dc.rightsopenAccess-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceInternational Journal of Molecular Sciences-
dc.titleStem cells therapy for spinal cord injury-
dc.typereview-
dc.identifier.doi10.3390/ijms19041039-
dc.identifier.scopus2-s2.0-85045031075-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

173

Downloads(s)

10

Files in This Item:
File Description SizeFormat 
10.3390-ijms19041039.pdf947.04 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons